Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Zhang, Xueli; Zhao, Yi; Chen, Shuobing; Shao, Hua

doi:10.1002/jcsm.12838

Cited by 28 publications

(14 citation statements)

References 101 publications

(175 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glucagon-like peptide 1(GLP-1) receptor agonists and dipeptidyl peptidase 4(DPP4) inhibitors seem to be favorable in protecting muscles. Although insulin can also increase muscle mass in patients with T2DM, the weight gain effect of insulin cannot be ignored, which should be carefully considered in the treatment of T2DM patients [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: a cohort study

Wei

Liu

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background The serum creatinine-to-cystatin C ratio (Scr/Scys) has been suggested as a surrogate marker of muscle mass and a predictor of adverse outcomes in many diseases. However, the prognostic value of Scr/Scys in patients with type 2 diabetes mellitus (T2DM) is unknown. The aim of this study is to assess the prognostic value of Scr/Scys in patients with T2DM. Methods In this retrospective observational study, we enrolled 3668 T2DM patients undergoing coronary angiography (CAG). Serum creatinine (Scr) and serum cystatin C (Scys) levels were measured at admission. The study population was separated into low muscle mass (low-MM) and normal muscle mass (normal-MM) groups by Scr/Scys cut-off point. The association between muscle mass and long-term all-cause mortality was examined using Cox regression analysis. Results During a median follow-up of 4.9 (3.0–7.1) years, a total of 352 (9.6%) patients died. The mortality was higher in patients with low-MM as compared with patients with normal-MM (11.1% vs. 7.3%; p < 0.001). Low muscle mass was associated with increased risk for long-term all-cause mortality, regardless of whether Scr/Scys were used as a continuous variable (adjusted hazard ratio: 1.08 [95% confidence interval (CI) 1.03 to 1.13]; p = 0.009) or a categorial variable (adjusted hazard ratio: 1.36 [95% CI 1.03 to 1.75]; p = 0.021). Conclusion Low muscle mass assessed by Scr/Scys was associated with increased risk of long-term all-cause mortality in diabetic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: a cohort study

Wei

Liu

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…In summary, the association between SGLT2i and sarcopenia was discussed. 19 . Some reports indicated pathological muscle loss, and others suggested elevated muscle strength.…”

Section: Discussionmentioning

confidence: 99%

Various clinical efficacy of sodium-glucose co-transporter-2 inhibitor (SGLT2i) to sarcopenia, muscle mass and function

Bando¹

2022

IJCAM

View full text Add to dashboard Cite

Regarding pharmacological therapy for diabetes, sodium-glucose co-transporter-2 inhibitor (SGLT2i) has been in focus for various clinical efficacy. They include cardiovascular disease, chronic heart failure (CHF) and chronic kidney disease (CKD). Various discussion has been observed concerning the relationship among diabetes, frailty, sarcopenia, SGLT2i, aging and senile syndrome. By SGLT2i, weight and visceral fat area (VFA) are decreased, and the results of skeletal muscle index (SMI) and bone mineral content (BMC) vary in some reports. Using abdominal CT, bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), muscle mass and BMC have been lately studied. SGLT2i may maintain muscle mass and function.

show abstract

“…Further studies should be carried out to confirm these findings. Other drugs frequently used by the elderly population to treat cardiovascular disorders do not appear to have a significant effect on sarcopenia ( Alturki et al, 2018 ; Zhang et al, 2021a ).…”

Section: A Brief Look At Nutritional and Medication In Sarcopeniamentioning

confidence: 99%

Anabolic-Androgenic Steroids and Exercise Training: Breaking the Myths and Dealing With Better Outcome in Sarcopenia

2022

View full text Add to dashboard Cite

Sarcopenia is an emerging clinical condition determined by the reduction in physical function and muscle mass, being a health concern since it impairs quality of life and survival. Exercise training is a well-known approach to improve physical capacities and body composition, hence managing sarcopenia progression and worsening. However, it may be an ineffective treatment for many elderly with exercise-intolerant conditions. Thus, the use of anabolic-androgenic steroids (AAS) may be a plausible strategy, since these drugs can increase physical function and muscle mass. The decision to initiate AAS treatment should be guided by an evidence-based patient-centric perspective, once the balance between risks and benefits may change depending on the clinical condition coexisting with sarcopenia. This mini-review points out a critical appraisal of evidence and limitation of exercise training and AAS to treat sarcopenia.

show abstract

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Cited by 28 publications

References 101 publications

Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: a cohort study

Prognostic value of creatinine-to-cystatin c ratio in patients with type 2 diabetes mellitus: a cohort study

Various clinical efficacy of sodium-glucose co-transporter-2 inhibitor (SGLT2i) to sarcopenia, muscle mass and function

Anabolic-Androgenic Steroids and Exercise Training: Breaking the Myths and Dealing With Better Outcome in Sarcopenia

Contact Info

Product

Resources

About